Prostate Cancer Stem Cells: A Target for New Therapies

  • N.  J. Maitland
  • S.  D. Bryce
  • M.  J. Stower
  • A.  T. Collins
Conference paper
Part of the Springer Series on Biofilms book series (SCHERING FOUND, volume 2006/5)


Prostate cancer is now a common disease in men over 50 years of age. Medical therapies for prostate cancer are based on discoveries from the mid-twentieth century, and in the long term are rarely curative. Most treatments are directed towards an androgen receptor-expressing, highly proliferative target cell, which does indeed form the vast majority of cells in a prostate tumour. However, by invoking the existence of a cancer stem cell which, like normal epithelial stem cells in the prostate, does not express androgen receptor and is relatively quiescent, the observed resistance to most medical therapies can be explained. The phenotype of the prostate cancer stem cells is that of a basal cell and cultures derived from cancers, but not benign tissues, express a range of prostate cancer-associated RNAs. Furthermore, stem cells purified on the basis of α2β1 high integrin and CD133 cell surface antigen expression, from an established culture of Gleason 4 (2+2) prostate cancer (P4E6), were able to form multiple intraprostatic tumours in nude mice when grafted orthotopically in a matrigel plug containing human prostatic stroma. The final tumours re-expressed androgen receptor and displayed a histology similar to that of a Gleason 4 cancer.


Prostate Cancer Androgen Receptor Cancer Stem Cell Stem Cell Population Luminal Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



We wish to thank Yorkshire Cancer Research and the National Cancer Research Institute for their continuing support of this work. Professors Freddy Hamdy and Nikki Brown (University of Sheffield) provided valuable and expert assistance in the xenograft technique, and Caty Hyde and Paul Berry processed the primary tissues and maintained the long-term cultures.


  1. Alt FW, Kellems RE, Bertino JR, Schimke RT (1978) Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J Biol Chem 253:1357–1370PubMedGoogle Scholar
  2. Beachy PA, Karhadkar SS, Berman DM (2004) Tissue repair and stem cell renewal in carcinogenesis. Nature 432:324–331CrossRefPubMedGoogle Scholar
  3. Bhatt RI, Brown MD, Hart CA, Gilmore P, Ramani VA, George NJ, Clarke NW (2003) Novel method for the isolation and characterisation of the putative prostatic stem cell. Cytometry A 54:89–99CrossRefPubMedGoogle Scholar
  4. Calabrese P, Tavare S, Shibata D (2004) Pretumor progression: clonal evolution of human stem cell populations. Am J Pathol 164:1337–1346CrossRefPubMedGoogle Scholar
  5. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33–39CrossRefPubMedGoogle Scholar
  6. Chipuk JE, Cornelius SC, Pultz NJ, Jorgensen JS, Bonham MJ, Kim SJ, Danielpour D (2002) The androgen receptor represses transforming growth factor-β signaling through interaction with Smad3. J Biol Chem 277:1240–1248CrossRefPubMedGoogle Scholar
  7. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM (2006) Cancer stem cells—perspectives on current status and future directions: AACR Workshop on Cancer Stem Cells. Cancer Res 66:9339–9344CrossRefPubMedGoogle Scholar
  8. Clarke RB, Spence K, Anderson E, Howell A, Okano H, Potten CS (2005) A putative human breast stem cell population is enriched for steroid receptor-positive cells. Dev Biol 277:443–456CrossRefPubMedGoogle Scholar
  9. Collins AT, Habib FK, Maitland NJ, Neal DE (2001) Identification and isolation of human prostate epithelial stem cells based on α2β1-integrin expression. J Cell Sci 114:3865–3872PubMedGoogle Scholar
  10. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946–10951CrossRefPubMedGoogle Scholar
  11. Corbeil D, Roper K, Hellwig A, Tavian M, Miraglia S, Watt SM, Simmons PJ, Peault B, Buck DW, Huttner WB (2000) The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 275:5512–5520CrossRefPubMedGoogle Scholar
  12. Cross SS, Hamdy FC, Deloulme JC, Rehman I (2005) Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology 46:256–269CrossRefPubMedGoogle Scholar
  13. Culig Z, Hobisch A, Cronauer MV, Cato AC, Hittmair A, Radmayr C, Eberle J, Bartsch G, Klocker H (1993) Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7:1541–1550CrossRefPubMedGoogle Scholar
  14. Cunha GR (1975) Age-dependent loss of sensitivity of female urogenital sinus to androgenic conditions as a function of the epithelia-stromal interaction in mice. Endocrinology 97:665–673CrossRefPubMedGoogle Scholar
  15. De Marzo AM, Meeker AK, Epstein JI, Coffey DS (1998) Prostate stem cell compartments. Am J Pathol 153:911–919CrossRefPubMedGoogle Scholar
  16. Dontu G, El-Ashry D, Wicha MS (2004) Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab 15:193–197CrossRefPubMedGoogle Scholar
  17. Feinberg AP, Ohlsson R, Henikoff S (2006) The epigenetic progenitor origin of human cancer. Nat Rev Genet 7:21–33CrossRefPubMedGoogle Scholar
  18. Franks LM (1954) Latent carcinoma of the prostate. J Pathol Bacteriol 68:603–616CrossRefPubMedGoogle Scholar
  19. Furr BJ (1996) The development of Casodex (biocalutamide) : pre-clinical studies. Eur Urol 29(Suppl:2):83–95PubMedGoogle Scholar
  20. Fuscoe JC, Fenwick RG Jr, Ledbetter DH, Caskey CT (1983) Deletion and amplification of the HGPRT locus in Chinese hamster cells. Mol Cell Biol 3:1086–1096PubMedGoogle Scholar
  21. Goldman J, Gordon M (2006) Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leuk Lymphoma 47:1–7CrossRefPubMedGoogle Scholar
  22. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM (1995) Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92:3439–3443CrossRefPubMedGoogle Scholar
  23. Hamburger AW, Salmon SE (1977) Primary bioassay of human tumor stem cells. Science 197:461–463CrossRefPubMedGoogle Scholar
  24. Hammacher A, Thompson EW, Williams ED (2005) Interleukin-6 is a potent inducer of S100P, which is up-regulated in androgen-refractory and metastatic prostate cancer. Int J Biochem Cell Biol 37:442–450CrossRefPubMedGoogle Scholar
  25. Heppner GH (1984) Tumor heterogeneity. Cancer Res 44:2259–2265PubMedGoogle Scholar
  26. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, Reuter V, Gerald WL (2004) Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164:217–227CrossRefPubMedGoogle Scholar
  27. Hudson DL, Guy AT, Fry P, O'Hare MJ, Watt FM, Masters JR (2001) Epithelial cell differentiation pathways in the human prostate: identification of intermediate phenotypes by keratin expression. J Histochem Cytochem 49:271–278PubMedGoogle Scholar
  28. Huggins C, Stevens RE Jr, Hodges CV (1941) Studies on prostate cancer: the effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43:209–223Google Scholar
  29. Isaacs JT, Coffey DS (1989) Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 2:33–50CrossRefPubMedGoogle Scholar
  30. Karin M (2006) Nuclear factor-κB in cancer development and progression. Nature 441:431–436CrossRefPubMedGoogle Scholar
  31. Kasper S (2005) Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis. J Cell Biochem 94:279–297CrossRefPubMedGoogle Scholar
  32. Lang SH, Stark M, Collins A, Paul AB, Stower MJ, Maitland NJ (2001) Experimental prostate epithelial morphogenesis in response to stroma and three-dimensional matrigel culture. Cell Growth Differ 12:631–640PubMedGoogle Scholar
  33. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, Park JK, Fine HA (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9:391–403CrossRefPubMedGoogle Scholar
  34. Lefrancois L, Marzo AL (2006) The descent of memory T-cell subsets. Nat Rev Immunol 6:618–623CrossRefPubMedGoogle Scholar
  35. Linja MJ, Visakorpi T (2004) Alterations of androgen receptor in prostate cancer. J Steroid Biochem Mol Biol 92:255–264CrossRefPubMedGoogle Scholar
  36. Liu AY, Roudier MP, True LD (2004) Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. Am J Pathol 165:1543–1556CrossRefPubMedGoogle Scholar
  37. Macintosh CA, Stower M, Reid N, Maitland NJ (1998) Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res 58:23–28PubMedGoogle Scholar
  38. Mackler NJ, Pienta KJ (2005) University of Michigan, Ann Arbor, MI, USA. Use of docetaxel in prostate and urothelial cancers. Nat Clin Pract Urol 2:92–100CrossRefPubMedGoogle Scholar
  39. MacLennan GT, Eisenberg R, Fleshman RL, Taylor JM, Fu P, Resnick MI, Gupta S (2006) The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. J Urol 176:1012–1016CrossRefPubMedGoogle Scholar
  40. Maitland NJ (2000) Targeting therapeutic gene expression to human prostate cancers. Curr Opin Mol Ther 2:389–399PubMedGoogle Scholar
  41. Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT (2006) Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 98:1134–1141CrossRefPubMedGoogle Scholar
  42. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB (2004) The role of inflammation in the pathogenesis of prostate cancer. J Urol 172:S6–11CrossRefPubMedGoogle Scholar
  43. Pardal R, Clarke MF, Morrison SJ (2003) Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3:895–902CrossRefPubMedGoogle Scholar
  44. Perez-Ordonez B, Beauchemin M, Jordan RC (2006) Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol 59:445–453CrossRefPubMedGoogle Scholar
  45. Pirson L, Baron F, Meuris N, Giet O, Castermans E, Greimers R, Di Stefano I, Gothot A, Beguin Y (2006) Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human CD133+ cells into NOD/SCIDbeta2mNull mice. Stem Cells 24:1814–1821CrossRefPubMedGoogle Scholar
  46. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT (2004) CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 117:3539–3545CrossRefPubMedGoogle Scholar
  47. Rybicki BA, Conti DV, Moreira A, Cicek M, Casey G, Witte JS (2004) DNA repair gene XRCC1 and XPD polymorphisms and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 13:23–29CrossRefPubMedGoogle Scholar
  48. Scaltriti M, Bettuzzi S, Sharrard RM, Caporali A, Caccamo AE, Maitland NJ (2004) Clusterin overexpression in both malignant and nonmalignant prostate epithelial cells induces cell cycle arrest and apoptosis. Br J Cancer 91:1842–1850CrossRefPubMedGoogle Scholar
  49. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821–5828PubMedGoogle Scholar
  50. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB (2004) Identification of human brain tumour initiating cells. Nature 432:396–401CrossRefPubMedGoogle Scholar
  51. Tannock IF, de Wit R, Berry WR, et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512CrossRefPubMedGoogle Scholar
  52. Thompson TC, Timme TL, Li L, Goltsov A (1999) Caveolin-1, a metastasis-related gene that promotes cell survival in prostate cancer. Apoptosis 4:233–237CrossRefPubMedGoogle Scholar
  53. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644–648CrossRefPubMedGoogle Scholar
  54. Winter SF, Cooper AB, Greenberg NM (2006) Models of metastatic prostate cancer: a transgenic perspective. Prostate Cancer Prostatic Dis 6:204–211CrossRefGoogle Scholar
  55. Wodinsky I, Swiniarski J, Kensler CJ (1968) Spleen colony studies of leukemia L1210. 3. Differential sensitivities of normal hematopoietic and resistant L1210 colony-forming cells to 6-mercaptopurine (NSC-755). Cancer Chemother Rep 52:251–255PubMedGoogle Scholar
  56. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson WG (2004) Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 64:1975–1986CrossRefPubMedGoogle Scholar
  57. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW (1997) AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90:5002–5012PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • N.  J. Maitland
    • 1
  • S.  D. Bryce
    • 1
  • M.  J. Stower
    • 2
  • A.  T. Collins
    • 1
  1. 1.Department of Biology, YCR Cancer Research UnitUniversity of YorkYorkUK
  2. 2.Department of UrologyYork HospitalYorkUK

Personalised recommendations